PMC

Dược phẩm Dược liệu Pharmedic ·HNX ·2026Q1

▼ Under pressure

Margins remain under pressure Net margin 14.75%, −2.11pp YoY
Price
134,900
Latest close
03 Jun 2026
P/E 20.16x
P/B 4.93x
EPS 6,693
BVPS 27,366
ROE 32.4%
ROA 22.7%
Profit Margin 14.8%
Asset Turnover 1.54x
Equity Mult. 1.43x

TTM · Applied to: EPS, ROE, ROA, Net Margin, Asset Turnover, Debt/Equity

What Is Changing

On a TTM 2026Q1 basis, PMC is holding revenue at an acceptable level, but margins are eroding visibly — margins have been compressing consistently over multiple periods. What is still missing is better cost control to prevent margin pressure from spreading to the overall profit result.

TTM REVENUE
VND 560bn
+7.1%YoY
NET MARGIN
14.75%
−2.1ppYoY
TTM NET PROFIT
VND 83bn
−6.4%YoY
Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24 Q1'24 Q4'23 Q3'23 Q2'23
Revenue 138.6 162.1 126.5 132.3 125.7 137.1 122.7 137.2 101.2 132.2 146.1 103.7
Growth -15% +28% -4% +5% -8% +12% -11% +36% -23% -9% +41%
Net Income 22.9 17.9 19.4 22.4 22.7 19.8 21.5 24.2 14.7 24.7 20.8 22.9
Net Margin 16.54% 11.02% 15.32% 16.91% 18.06% 14.42% 17.51% 17.63% 14.52% 18.68% 14.21% 22.13%

Drivers of PMC's profit

TTM

Net profit attributable to parent declined vs last year, mainly due to higher selling expenses. Supporting and offsetting drivers:

Gross profit ↑ 23.5bn
Tax ↓ 1.4bn
Selling expenses ↑ 12.7bn
Administrative expenses ↑ 10.2bn
Financial income ↓ 7.0bn
TTM

Net profit attributable to parent increased vs prior quarter, mainly helped by higher gross profit. Supporting and offsetting drivers:

Gross profit ↑ 6.4bn
Administrative expenses ↑ 2.0bn
Selling expenses ↑ 1.8bn
Financial income ↓ 1.2bn
Other profit ↓ 0.7bn

Financial Highlights

Detailed analysis of each financial dimension

ROE = Profit Margin × Asset Turnover × Equity Multiplier

2025Q1 29.7% = 16.9% × 1.42 × 1.24
2026Q1 32.4% = 14.8% × 1.54 × 1.43

ROE rose from 29.7% to 32.4% — mainly driven by leverage, despite net margin moving in the opposite direction.

Net margin: 14.8% -2.1pp Asset turnover: 1.54x +0.11x Leverage: 1.43x +0.19x

Is the profit sustainable?

Margins narrowed but earnings quality remains clean — pressure is mainly operational.

very positive positive stable watch under pressure

What is driving the margin?

Net margin fell to 14.75%, losing 2.1pp. The main pressure is SG&A / Revenue rose 2.8pp, outweighing the improvement in Gross margin rose 1.6pp (in addition, Other profit / Revenue rose 0.0pp added support while Net financial result / Revenue fell 1.5pp remained a drag).

The pressure comes from non-core items while core operations hold their rhythm — margin has a basis to recover once this factor passes.

Profitability trend

Net Margin 14.75% −2.1pp
Gross Margin 41.04% +1.6pp
SG&A / Revenue 23.08% +2.8pp

TTM YoY · 2025Q1 -> 2026Q1

Is capital being used efficiently?

Capital efficiency should be read in industry context — ROIC may fluctuate with business specifics.

Is capital being deployed efficiently?

Track how much operating profit the business generates on invested capital.

Industry characteristics make ROIC cyclical — this is a reference signal and should be read with the business context.

CAPITAL EFFICIENCY TREND

TTM YoY · 2025Q1 -> 2026Q1

ROIC
NOPAT Margin 14.63% −2.1pp
Capital Turnover
Average Invested Capital

Balance Sheet

ROIC above should be read with industry context — the balance sheet below adds perspective. Capital structure is conservative with low leverage — liabilities at 0.43x equity, net debt at 0.06x equity.

Inventory ended the period at 103.9bn, roughly 30.1% of total assets.

Over the last 12 months, working capital absorbed 60.6bn of cash, mainly because of higher receivables and higher inventories. Part of that drag was offset by higher payables.

Working Capital Drivers

TTM YoY · 2025Q1 -> 2026Q1

Receivables increased → lower CFO: −45.4bn
Inventories increased → lower CFO: −29.0bn
Payables increased → higher CFO: +13.9bn

Working Capital Efficiency

Cash conversion cycle lengthened by 18.8 days versus the same period last year. The main moves came from DIO rose 20.7 days, DSO rose 5.3 days, and DPO rose 7.2 days.

Working capital cycle lengthened mainly due to slower inventory turnover — more capital is being tied up in inventory.

Watchpoints

Cash conversion cycle remains stretched

CCC stands at 112.2 days, suggesting that working capital remains tied up for a relatively long operating cycle.

Receivables collection is slowing

DSO increased by +5.3 days, pointing to slower receivables turnover.

Working Capital Efficiency

TTM YoY · 2025Q1 -> 2026Q1

Receivables 25.8 days +5.3 days
Inventory 121.3 days +20.7 days
Payables 34.9 days +7.2 days
Cash Conversion Cycle 112.2 days +18.8 days

Is financial risk significant?

Leverage is safe but FCF is negative at 97.3bn due to capex of 85.2bn — an investment choice, not an urgent risk.

Leverage & Liquidity

Track net leverage, interest coverage, and the liquidity buffer on the balance sheet.

At present, short-term debt accounts for 100.0% of total debt, cash equals 75.5% of debt, and total debt stands at 58.3bn.

Watchpoints

Short-term refinancing pressure is meaningful

Short-term debt accounts for 100.0% of total debt, raising near-term refinancing needs.

Leverage and liquidity trend

Net Debt / Equity 0.06x
Interest Coverage
Cash / Debt 75.5%
Short-term Debt / Total Debt 100.0%
CFO / NI -0.15x −0.76x

TTM YoY · 2025Q1 -> 2026Q1

Cash Flow

With safe leverage noted above, cash flow below shows the self-funding capacity. Operating cash flow reached 20.7bn in 2025, against investing cash flow of 68.0bn.

Post-investment cash flow was positive +88.8bn. Financing cash flow was negative +108.3bn.

CFO / net income was -0.15x.

After spending +85.2bn on fixed-asset investment, the business generated trailing free cash flow of −97.3bn.

Cash Conversion

TTM Cash Conversion · 2025Q1 -> 2026Q1

CFO TTM 12.1bn −66.6bn
Cash Capex 85.2bn +70.7bn
FCF TTM −97.3bn −137.3bn

Investment Takeaway

The business is under real pressure, but the current picture has not turned broadly adverse. A notable area has clearly weakened, making the near-term outlook hard to call bright; even so, other parts of the business are still holding up, with margins remain under pressure remaining the main constraint, with net margin down 2.1 pp. The next watchpoint is capital efficiency. The main offsetting support comes from earnings conversion is confirmed, with CFO/NI at -0.15x.

Improvement: earnings conversion looks more confirmed, with CFO / net income at -0.15x.

Watchpoint: Capital efficiency needs cycle context.

Key risk: profitability remains under pressure, with trailing-12M net margin at 14.75% after a 2.1pp decline versus the same period last year.

Statement Data

Item 2025 2024 2023 2022 2021
Net Revenue
546.6 498.2 485.2 472.3 414.2
Cost of Goods Sold
323.4 311.0 315.1 285.9 0.0
Gross Profit
223.2 187.2 170.1 186.4 147.5
Financial Expenses
0.3 0.0 0.0 0.1 -0.0
Selling Expenses
63.0 47.1 45.1 49.7 -39.2
General and Administrative Expenses
62.3 49.6 40.6 45.9 -35.7
Operating Profit
101.5 100.0 104.3 103.9 82.0
Profit Before Tax
103.0 100.3 104.6 104.5 81.3
Net Income
82.3 80.1 83.6 83.4 64.8
Profit Attributable to Parent
82.3 80.1 83.6 83.4 64.8
Earnings per Share
6,438.00 6,268.00 6,536.00 6,525.00 5,263.00

Explore Other Stocks In The Same Sector

DHG, DVN, IMP, DBD, DTP, TRA, DMC, DP3, OPC, NDC, DAN, VDP, DHT, FIT, DHD, AGP, DVM, CNC, PBC, LDP, DPH, VMD, NDP, HDP, DCL, PPP, VET, MTP, MKV, DHN, MED, DBT, DTG, DPP, BIO, VNY, DBM, MKP, TW3, DTH, NTF, BCP, UPH, SPM, DP2, VXP

Need support? If you need support with content lookup or want to provide feedback about content on the website, please contact us below.